Inflammatory Bowel Disease

Immunology·MeSH: Inflammatory Bowel Diseases

Prevalence

0.1 / 100K

24 drugs in development·21 companies·5 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
labeling	ACURA PHARMACEUTICALS, INC (ACUR)

Phase 3(1)

Drug	Company
imu-856	IMMUNIC, INC. (IMUX)

Phase 2(9)

Drug	Company
fxr314	VivoSim Labs, INC. (VIVS)
isomyosamine	Q/C TECHNOLOGIES, INC. (QCLS)
morf-057	Morphic Holding, Inc. (MORF)
MORF-057	ELI LILLY & Co (LLY)
pl8177	PALATIN TECHNOLOGIES INC (PTN)
SER-287	Seres Therapeutics, Inc. (MCRB)
SPY120	Spyre Therapeutics, Inc. (SYRE)
SPY130	Spyre Therapeutics, Inc. (SYRE)
SPY230	Spyre Therapeutics, Inc. (SYRE)

Phase 1(3)

Drug	Company
disc-0974	Disc Medicine, Inc. (IRON)
sl-425	Shattuck Labs, Inc. (STTK)
wtx-921	Werewolf Therapeutics, Inc. (HOWL)

Preclinical(8)

Drug	Company
ABS-101	Absci Corporation (ABSI)
fin-524	Finch Therapeutics Group, Inc. (FNCH)
ht-003	Hoth Therapeutics, Inc. (HOTH)
imx-120	Immix Biopharma, Inc. (IMMX)
kind-509	Kindred Biosciences, Inc. (KIN)
KT-294	Kymera Therapeutics, Inc. (KYMR)
ser-603	Seres Therapeutics, Inc. (MCRB)
zegocractin (oral, preclinical administration)	CalciMedica, Inc. (CALC)

Unknown(1)

Drug	Company
guselkumab	Innovation Pharmaceuticals Inc. (IPIX)

BLA Filed(1)

Drug	Company
Icotyde	Protagonist Therapeutics, Inc (PTGX)

BioSniper tracks 24 drugs in development for Inflammatory Bowel Disease across 21 companies.

There are 5 clinical trials targeting Inflammatory Bowel Disease tracked by BioSniper.

The estimated prevalence of Inflammatory Bowel Disease is approximately 0.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.